| Literature DB >> 36186459 |
Fen Tang1, Zhou Zhou1, Kongqian Huang1, Wen Deng1, Jiali Lin1, Ruoyun Chen1, Min Li1, Fan Xu1.
Abstract
Th17 and regulatory T cells (Tregs) play crucial roles in the pathogenesis of autoimmune diseases. Th17/Treg homeostasis is critically involved in maintaining the immune balance. Disturbed Th17/Treg homeostasis contributes to the progression of autoimmune diseases. MicroRNAs (miRNAs) have emerged as a new vital factor in the regulation of disturbed Th17/Treg homeostasis. To better understand the epigenetic mechanisms of miRNAs in regulating Treg/Th17 homeostasis, we included and evaluated 97 articles about autoimmune diseases and found that miRNAs were involved in the regulation of Treg/Th17 homeostasis from several aspects positively or negatively, including Treg differentiation and development, Treg induction, Treg stability, Th17 differentiation, and Treg function. Uveitis is one of the ocular autoimmune diseases, which is also characterized with Th17/Treg imbalance. However, our understanding of the miRNAs in the pathogenesis of uveitis is elusive and not well-studied. In this review, we further summarized miRNAs found to be involved in autoimmune uveitis and their potential role in the regulation of Th17/Treg homeostasis.Entities:
Keywords: Th17 cells; Treg cells; autoimmunity; intermediate; microRNAs; posterior; uveitis (MeSH)
Year: 2022 PMID: 36186459 PMCID: PMC9515448 DOI: 10.3389/fgene.2022.848985
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.772
FIGURE 1Flow diagram for systematic review.
FIGURE 2miRNAs involved in Treg differentiation and development.
FIGURE 3miRNAs in Treg induction and Th17 differentiation.
miRNAs involved in uveitis pathogenesis by regulating Treg/Th17 homeostasis in animals.
| Author | Species | Type of uveitis | miRNA | Potential role |
|---|---|---|---|---|
| MX | Rats | EAU | miR-223-3p (↑) | Regulating the transcription factor Rbpj on the differentiation of Th1 and Th17 cells |
|
| Mice | EAU | miR-21-5p (↑) | Regulating the Th17/Treg balance |
| Yankai | Mice | EAU | miR-223-3p (↑) | Promotes autoreactive Th17 cell responses by inhibiting FOXO3 expression |
|
| Mice | EAU | miR-155 | Promote the expansion of pathogenic Th17 cells with STAT3 |
|
| Mice | EAU | miR-142-5p and miR-21 (↑); miRNA-182 (↓) | Regulating Th17 development by affecting IL-17 |
| Yuanyuan | Rats | EAU | miR-30b-5p (↓) | Regulating the level of IL-10- and TLR4-positive cells |
| T | Rats | EAU | miR-223 and miR-146a (↑); miRNA-181a (↓) | Associated with the elevation of IL-1β/MCP-1 |
|
| Rats | EAU | miR-146a (↑) | Reduce inflammation by downregulating IL-1 |
Experimental autoimmune uveitis (EAU); (↑) upregulated; (↓) downregulated.
miRNAs involved in uveitis pathobiology by regulating Treg/Th17 in humans.
| Author | Species | Type of uveitis | miRNA | Potential role |
|---|---|---|---|---|
| G | Humans | Behçet’s disease | miR-326 (↑); miR-21 and miR-146b (↓) | Used as a biomarker for the prediction of uveitis and severe eye involvement |
| Rui | Humans | VKH | miR-20a-5p (↓) | Suppressing the production of IL-17 by targeting OSM and CCL1 production in CD4+ T cells |
| Sousan | Humans | Behçet’s disease | miR-155 and miR-146a (↑) | Associated with the upregulation of TNF-α and downregulation of CTLA-4 genes |
| Majid | Humans | Behçet’s disease | miR-25, miR-106b, miR326, and miR93 (↑); miR-146a, and miR-155 (↓) | Associate with the Th17/Treg frequency and act as a prognostic biomarker |
|
| Humans | Behçet’s disease and VKH | miR-182 (↑) | As regulatory factors for Treg cell development and function |
| So Young | Humans | Behçet’s disease | miR-155 (↑) | Regulating the Th17 immune response by targeting Ets-1 |
| Min Yeong | Humans | Behçet’s disease | miR-3591-3p (↑); miR-638 and miR-4488 (↓) | Increasing IL-6 mRNA levels in Th-1 cells in response to LPS stimulation |
| Qingyun | Humans | VKH syndrome | miR-146a (↓) | Strong association with IL-17, TNF-α, and IL-1β production |
| Qingyun | Humans | Behçet’s disease | miR-155 (↓) | Inhibiting the production of IL-6 and IL-1β, promoting the expression of IL-10, and inhibiting intracellular IL-17 expression in allogeneic CD4+ T cells by targeting TAB2 |
Vogt–Koyanagi–Harada (VKH) syndrome.